We manufacture and market a large basket of pharmaceutical formulations across chronic and acute therapies, including generics, branded generics, specialty & complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Our portfolio spans multiple dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. With billions of doses delivered annually across our key therapeutic areas like neuro-psychiatry, cardiology, gastroenterology, anti-infectives diabetology, oncology, ophthalmology, dermatology, urology, nephrology, respiratory, and more, we are helping improve access to medicine globally.
Recent Posts
- Sun Pharma reports Q1FY26 results
- Sun Pharma’s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint
- Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
- Sun Pharma Brings Back Its #SecondBirthDate Campaign on National Doctors’ Day
- Sun Pharma appoints Kirti Ganorkar as the Managing Director; Dilip Shanghvi to continue as the Executive Chairman of the Board
Recent Comments